At the International Conference on Cancer Science and Research (November 17–19, 2025) in Singapore and Online, Dr. Sergey Reva from Pavlov First Saint Petersburg State Medical University, Russian Federation, presented an insightful study exploring the role of immunological markers as predictors of unfavorable outcomes in prostate cancer patients undergoing radical prostatectomy.
His research shed new light on how systemic inflammation markers
— including Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte
Ratio (PLR), and Lymphocyte-Monocyte Ratio (LMR) — could potentially
indicate tumor aggressiveness and disease progression.
🔍 Key
Takeaways from the Study
- 🧬 Systemic Inflammation
in Cancer: The study reinforced that inflammation plays a crucial role
in cancer development and progression, influencing tumor biology and
patient outcomes.
- 📈 Clinical
Analysis: Conducted on 74 prostate cancer patients treated with
laparoscopic radical prostatectomy, with data collected on
preoperative blood markers.
- 🔢 Significant
Findings:
- Patients with NLR > 1.67 showed a higher risk of
locally advanced disease (pT3 or higher) (p=0.0241).
- A PLR > 113.8 was linked to high-grade prostate cancer
(ISUP 4–5) (p=0.0416).
- ⚖️ No Strong
Correlation Found: Between these markers and postoperative features
like upstaging, risk group increase, or lymph node
involvement (p>0.05).
- 💡 Overall
Conclusion: Elevated NLR and PLR values can be used as predictive
indicators for more aggressive forms of prostate cancer, aiding
in patient stratification and treatment planning.
👨⚕️ About the Researcher
Dr. Sergey Reva is a prominent
oncologist and urologist, holding a PhD in Oncology from N.N.
Petrov Research Institute of Oncology. He serves as the Chairman of the
Urooncological Department at Pavlov First Saint Petersburg State Medical
University. His main research interests revolve around prostate and
bladder cancer, and he is affiliated with leading organizations like the European
Association of Urology (EAU), Société Internationale d'Urologie (SIU),
and American Urological Association (AUA).
With more than 20 scientific publications, Dr. Reva continues to
contribute valuable insights to the field of uro-oncology and cancer
immunology.
🌐 Conference
Information
📅 Event: International
Conference on Cancer Science and Research
📍 Venue:
Singapore & Online
🔗 Website: https://cancer.miconferences.com/
📨 Email:
cancer@mathewsconference.com
📱 Phone: +1
(312) 462-4448
💬 WhatsApp:
+1 (424) 377 0967
📝 Registration:
Click
Here
🧾 Abstract
Submission: Click
Here
🐦 Follow Updates:
@CancerWorldConf